Glioblastoma presents roadblock to successful immunotherapy

SEATTLE — Although advancements have been made in immune checkpoint inhibitors, tumors such as glioblastoma present a roadblock to successful therapy, according to a presenter at the 2022 American Academy of Neurology annual meeting.
“Inhibitors have really revolutionized oncology in the past 10 years with various different indications,” Priya Kumthekar, MD, associate professor at Northwestern University Feinberg School of Medicine, said during a presentation. “Unfortunately [with] glioblastoma, checkpoint inhibition has not quite made the same impact.”
Immune

SEATTLE — Although advancements have been made in immune checkpoint inhibitors, tumors such as glioblastoma present a roadblock to successful therapy, according to a presenter at the 2022 American Academy of Neurology annual meeting.
“Inhibitors have really revolutionized oncology in the past 10 years with various different indications,” Priya Kumthekar, MD, associate professor at Northwestern University Feinberg School of Medicine, said during a presentation. “Unfortunately [with] glioblastoma, checkpoint inhibition has not quite made the same impact.”
Immune